We are live on ! Find out more
PTIXW

Protagenic Therapeutics Warrant
PTIXW

Delisted

PTIXW was delisted on the 2nd of January, 2026.

Back to rankings

3 hedge funds and large institutions have $53K invested in Protagenic Therapeutics Warrant in 2022 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 0 increasing their positions, 1 reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

50% more funds holding

Funds holding: 2 → 3 (+1)

0.08% less ownership

Funds ownership: 2.14% → 2.06% (-0.08%)

32% less capital invested

Capital invested by funds: $78K → $53K (-$25K)

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 1

Holders
3
Holders Change
+1
Holders Change %
+50%
% of All Funds
0.05%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
–
Reduced
1
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$3.46K

Top Sellers

Rank Fund Capital Flow
1
WAM
Warberg Asset Management
Illinois
-$4.38K
Name Holding Trade Value Shares
Change 		Change in
Stake
WAM
1
Warberg Asset Management
Illinois
$49K -$4.38K -33,843 -9%
Susquehanna International Group
2
Susquehanna International Group
Pennsylvania
$4K +$3.46K +26,719 New

PTIXW Hedge Fund Activity: Q2 2022 in Review

3 of the 5,937 institutional investors tracked by Wall St. Rank reported a position in Protagenic Therapeutics Warrant (PTIXW) for Q2 2022, worth a combined $53K — down 32% from $78K a quarter earlier.

Buyers outnumbered sellers: 1 fund opened new PTIXW positions and 0 closed out — a net gain of 1 holder — while 0 added to existing stakes and 1 trimmed.

The largest buyer was Susquehanna International Group, opening a new position worth an estimated $3.46K. The largest seller was Warberg Asset Management, cutting an estimated $4.38K.

  • 3 institutional investors held Protagenic Therapeutics Warrant (PTIXW) as of Q2 2022, up from 2 in Q1 2022.
  • Funds reported $53K of Protagenic Therapeutics Warrant stock for Q2 2022, down 32% quarter-over-quarter.
  • 1 fund opened new Protagenic Therapeutics Warrant positions in Q2 2022 and 0 closed out, a net change of +1 holder.
  • The largest Protagenic Therapeutics Warrant buyer in Q2 2022 was Susquehanna International Group, an estimated $3.46K added.
  • The largest Protagenic Therapeutics Warrant seller in Q2 2022 was Warberg Asset Management, an estimated $4.38K sold.

Based on aggregated 13F filings for Q2 2022.